HC Wainwright Issues Pessimistic Outlook for HRTX Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS forecast for Heron Therapeutics to a loss of $0.15 per share from $0.14, while maintaining a Neutral rating.
• Heron’s latest quarter matched analysts’ EPS estimate at a loss of $0.03 per share, but revenue of $35.25 million came in below the $37.5 million consensus.
• Analyst sentiment is generally cautious: MarketBeat reports a consensus “Reduce” rating and a $2.00 price target, with three Hold ratings and one Sell rating.

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - HC Wainwright lowered their FY2026 earnings per share estimates for Heron Therapeutics in a research note issued on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings per share of ($0.15) for the year, down from their prior estimate of ($0.14). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Heron Therapeutics' Q4 2026 earnings at ($0.04) EPS, FY2027 earnings at ($0.14) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at ($0.03) EPS.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Heron Therapeutics in a report on Thursday, October 15th. Zacks Research raised Heron Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, August 3rd. Finally, Wall Street Zen raised Heron Therapeutics to a "sell" rating in a report on Saturday, August 8th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Heron Therapeutics currently has a consensus rating of "Reduce" and a consensus price target of $2.00.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $0.33 on Friday. The company has a market cap of $62.01 million, a PE ratio of -2.72 and a beta of 1.65. Heron Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.57. The firm has a 50-day simple moving average of $0.33 and a 200 day simple moving average of $0.65. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 32.59.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). Heron Therapeutics had a negative net margin of 14.55% and a negative return on equity of 277.36%. The company had revenue of $35.25 million for the quarter, compared to the consensus estimate of $37.50 million.

Hedge Funds Weigh In On Heron Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. HORAN Wealth LLC bought a new position in shares of Heron Therapeutics during the first quarter worth about $33,000. Deutsche Bank AG bought a new stake in Heron Therapeutics in the 2nd quarter valued at about $41,000. Ieq Capital LLC bought a new stake in Heron Therapeutics in the 2nd quarter valued at about $41,000. Bank of America Corp DE bought a new stake in Heron Therapeutics in the 2nd quarter valued at about $46,000. Finally, Persistent Asset Partners Ltd acquired a new position in Heron Therapeutics during the 2nd quarter valued at about $50,000. Institutional investors and hedge funds own 80.01% of the company's stock.

About Heron Therapeutics

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company's portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.